CLINICAL_TRIALS ClinicalTrials.gov record update

A First-in-human Phase 1 Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07458347
Title field or adapter rule: {'original_value': 'A First-in-human Phase 1 Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:23.305491+00:00
Published At: 2026-10-15T00:00:00+00:00
Record Updated At: 2026-10-15
Source Retrieved At: 2026-10-31T22:17:52.415050+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["KRAS-mutant Non-small Cell Lung Cancer (NSCLC)", "KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)", "KRAS-mutant Colorectal Cancer (CRC)", "Other KRAS-mutant Solid Tumors"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-15", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT07458347"
protocolSection.identificationModule.officialTitle: "A First-in-human Phase 1 Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['KST-6051 Dose Escalation Combination Therapy with Cetuximab', 'KST-6051 Dose Escalation Combination Therapy with Gemcitabine/Nab-paclitaxel', 'KST-6051 Dose Escalation Combination Therapy with Pembrolizumab', 'KST-6051 Dose Escalation Monotherapy', 'KST-6051 Dose Expansion Combination Therapy with Cetuximab', 'KST-6051 Dose Expansion Combination Therapy with Cetuximab and mFOLFOX6 or FOLFIRI', 'KST-6051 Dose Expansion Combination Therapy with Gemcitabine/nab-paclitaxel', 'KST-6051 Dose Expansion Combination Therapy with Pembrolizumab and Pemetrexed/carboplatin', 'KST-6051 Dose Expansion Monotherapy in Later-line Settings', 'KST-6051 Dose Expansion Monotherapy in NSCLC After 1 or 2 Prior Lines of Therapy', 'KST-6051 Dose Expansion Monotherapy in PDAC After 1 or 2 Prior Lines of Therapy', 'KST-6051 Dose Expansion Monotherapy in Prior RAS/KRAS Inhibitor-treated Solid Tumors', 'KST-6051 Dose Expansion Monotherapy in mCRC After 1 or 2 prior Lines of Therapy'], 'description': 'KST-6051 will be administered orally as a tablet.', 'name': 'KST-6051', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['KST-6051 Dose Escalation Combination Therapy with Gemcitabine/Nab-paclitaxel', 'KST-6051 Dose Expansion Combination Therapy with Gemcitabine/nab-paclitaxel'], 'description': 'Gemcitabine/nab-paclitaxel will be administered intravenously (IV).', 'name': 'Gemcitabine/nab-paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['KST-6051 Dose Escalation Combination Therapy with Cetuximab', 'KST-6051 Dose Expansion Combination Therapy with Cetuximab', 'KST-6051 Dose Expansion Combination Therapy with Cetuximab and mFOLFOX6 or FOLFIRI'], 'description': 'Cetuximab will be administered IV.', 'name': 'Cetuximab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['KST-6051 Dose Escalation Combination Therapy with Pembrolizumab', 'KST-6051 Dose Expansion Combination Therapy with Pembrolizumab and Pemetrexed/carboplatin'], 'description': 'Pembrolizumab will be administered IV.', 'name': 'Pembrolizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['KST-6051 Dose Expansion Combination Therapy with Cetuximab and mFOLFOX6 or FOLFIRI'], 'description': 'mFOLFOX6 will be administered IV.', 'name': 'mFOLFOX6', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['KST-6051 Dose Expansion Combination Therapy with Cetuximab and mFOLFOX6 or FOLFIRI'], 'description': 'FOLFIRI will be administered IV.', 'name': 'FOLFIRI', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['KST-6051 Dose Expansion Combination Therapy with Pembrolizumab and Pemetrexed/carboplatin'], 'description': 'Pemetrexed will be administered IV.', 'name': 'Pemetrexed', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['KST-6051 Dose Expansion Combination Therapy with Pembrolizumab and Pemetrexed/carboplatin'], 'description': 'Carboplatin will be administered IV.', 'name': 'Carboplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.